New In MDS

Our "New in MDS" articles cover treatment option updates, coverage of advancements from MDS academic meetings, and more.

Recent Articles

A New Treatment Option Being Investigated For High Risk MDS And AML Patients

November 09, 2023

mds, aml, Bemcentinib, new in mds, life with mds, new treatment for HR-MDS

The Use Of Antithymocyte Globulin Immunotherapy When Treating Low-Risk MDS

October 03, 2023

Immunosuppressive therapy can be an option for patients with lower-risk MDS (LR-MDS). A common type of immunotherapy for MDS is antithymocyte globulin (ATG).

Reblozyl Receives FDA Approval As First-Line Treatment Of Anemia In Lower-Risk MDS Patients

August 29, 2023

Reblozyl, a first-in-class erythroid maturation agent, has been approved to treat MDS related anemia in ESA-naive patients with LR-MDS.

Sabatolimab in Patients with Very High/High-Risk MDS and AML

July 11, 2023

Sabatolimab binds to the surface of T-cells, releasing the breaks that the tumor applied to the immune system.

Omidubicel Granted FDA Approval For Use In Stem Cell Transplants

May 23, 2023

For more than 30 years, umbilical cord blood (UCB) has been an important stem cell source for patients with leukemia, lymphoma and MDS

Dr. Sekeres - Improving Treatment for Myelodysplastic Syndromes (MDS)

May 02, 2023

Dr. Sekeres shared with us what he and his MDS colleagues are focusing their research on right now.

Dr. Chandhok - Improving Drug Efficacy for Underserved Populations

April 25, 2023

Dr. Chandhok is doing important research into improving drug efficacy for underserved populations.

Dr. Tinsley Vance - Improving Patient Treatment Experience

April 18, 2023

The work Dr. Tinsley Vance is doing is important and will have a big impact on the way we look at patient decision making and our support of caregivers.